Anika Therapeutics Transforms to Hybrid Commercial Model

By Mike Evers

In 3Q19, Anika completed the buildout of their U.S. hybrid commercial model while achieving double-digit revenue growth driven by MONOVISC and CINGAL.

Member-Only Content

SUBSCRIBE Login

Product Labels: Viscosupplement

Tags: Revenue Report